Sunday, December 04, 2016 7:59:39 PM
EDIT GeneEditing...Biotechnology...the ability to play God...
3 stocks... Intellia Therapeutics Inc.(NTLA) and CRISPR Therapeutics Ltd. (CRSP). Editas Medicine Inc. (EDIT). All three companies went public this year.
Gene-Editing Revolution: What Is CRISPR-Cas9?
http://www.investopedia.com/articles/investing/022616/geneediting-revolution-what-crisprcas9.asp
In human hands, this ability amounts to what's known in common parlance as playing God. It offers an enormous improvement on existing gene therapies: researchers have played around with treatments for HIV, Huntington's, hemophilia, cancer and horrific rare diseases such as Sanfillipo. It has agricultural applications that would make Monsanto Co.'s (MON) mouth water. It also offers the ability, in theory, to do incredibly useful things like shut down the ability of mosquitoes to transmit diseases.
Researchers have used CRISPR on macaques, sorghum, zebra fish, rice and other species. They've treated liver disease in mice. A Chinese team has used CRISPR to edit a non-viable human embryo.
Read more: The Gene-Editing Revolution: What Is CRISPR-Cas9? | Investopedia http://www.investopedia.com/articles/investing/022616/geneediting-revolution-what-crisprcas9.asp#ixzz4Ruzkfihm
http://www.investopedia.com/news/first-human-crispr-geneediting-test-conducted-china-crsp-edit/?partner=YahooSA
A team led by Lu You, an oncologist at Sichuan University in Chengdu, China, has conducted the first human trial of a controversial new gene-editing technology known as CRISPR-Cas9. On October 28, the team injected modified immune cells into a patient with aggressive lung cancer, Nature reported Tuesday afternoon. Carl June, an immunotherapy specialist at the University of Pennsylvania, told the journal he expects the trial "to trigger 'Sputnik 2.0,' a biomedical duel on progress between China and the United States."
Using CRISPR, the team removed the protein PD-1 from immune cells taken from the patient's blood. PD-1 inhibits the immune system's response, allowing tumors to grow. By re-injecting these altered cells, they hope to coax the immune system into attacking the cancer as a disease.
CRISPR's potential applications are already bewildering. It is, in essence, a pair of molecular scissors, which can be used to cut certain strands of DNA out of a sequence and replace them with others. The process often turns out to be imprecise in practice, but at less than five years old, the technology is in its early stages. It is not difficult to envision a future in which scientists can selectively modify any portion of an animal or plant's genome as easily as they might tweak software code. That means increasing crop yields, treating rare genetic diseases for which it's impractical or impossible to develop conventional therapies, rendering disease-carrying pests harmless, and choosing the color of your baby's eyes.
That last example has understandably caused some hang-ups. Many scientists worry about the implications of being able to "design" not just super-productive corn or malaria-free mosquitos, but human beings. The potential pitfalls range from unintended side-effects to a full-fledged eugenics campaign. Poor parents would be unlikely to get to boost their children's height, speed or intelligence, as rich parents may one day be able to do, so economic inequality could take on a genetic element. Most scientists vehemently oppose the use of CRISPR on genes that can be passed on – the "germline" – since, as a number of researchers wrote in a Nature op-ed in March, such modifications "could have unpredictable effects on future generations."
According to Eric Juengst, director of the University of North Carolina Center for Bioethics, the October 28 human trial "does not put the germ-line at risk," so it does not play into the most controversial questions surrounding the technology. "In fact," he told Investopedia via email Tuesday, "similar 'cancer vaccination' protocols have been a common exercise in gene therapy since the 90s." He pointed to a different set of Chinese experiments as a source of controversy, however: in April 2015, it emerged that researchers at Sun Yat-sen University in Guangzhou had modified human germ-line embryo cells. While these were non-viable embryos, many saw the study as crossing a red line.
Besides the ethical questions, there is a question of who owns the intellectual property underpinning a potentially $1.5 billion market (Reportlinker's estimate for 2022). The main contenders are Jennifer Doudna and Emmanuelle Charpantier of Berkeley and Feng Zhang of MIT's Broad Institute. Oral arguments in a dispute between the two sides are set to begin on Thursday. The Berkeley faction is tied to two publicly traded companies, Intellia Therapeutics Inc. (NTLA) and CRISPR Therapeutics Ltd. (CRSP). The Broad Insititute is tied to to Editas Medicine Inc. (EDIT). All three companies went public this year.
Read more: First Human CRISPR Gene-Editing Test Conducted in China (CRSP, EDIT) | Investopedia http://www.investopedia.com/news/first-human-crispr-geneediting-test-conducted-china-crsp-edit/#ixzz4RuwyXIV2
Those interested...the charts below are trying to define themselves "relative" to the 50 day moving average...=BULL above the 50 day...Bear below the 50day...anyone or all of these could become one of those multi-year WOW! stocks...
http://stockcharts.com/c-sc/sc?s=NTLA&p=D&b=5&g=0&i=p18707943583&r=1480898230962
http://stockcharts.com/c-sc/sc?s=CRSP&p=D&b=5&g=0&i=p15600642353&r=1480898336392
http://stockcharts.com/c-sc/sc?s=EDIT&p=D&b=5&g=0&i=p25126586455&r=1480898404309
3 stocks... Intellia Therapeutics Inc.(NTLA) and CRISPR Therapeutics Ltd. (CRSP). Editas Medicine Inc. (EDIT). All three companies went public this year.
Gene-Editing Revolution: What Is CRISPR-Cas9?
http://www.investopedia.com/articles/investing/022616/geneediting-revolution-what-crisprcas9.asp
In human hands, this ability amounts to what's known in common parlance as playing God. It offers an enormous improvement on existing gene therapies: researchers have played around with treatments for HIV, Huntington's, hemophilia, cancer and horrific rare diseases such as Sanfillipo. It has agricultural applications that would make Monsanto Co.'s (MON) mouth water. It also offers the ability, in theory, to do incredibly useful things like shut down the ability of mosquitoes to transmit diseases.
Researchers have used CRISPR on macaques, sorghum, zebra fish, rice and other species. They've treated liver disease in mice. A Chinese team has used CRISPR to edit a non-viable human embryo.
Read more: The Gene-Editing Revolution: What Is CRISPR-Cas9? | Investopedia http://www.investopedia.com/articles/investing/022616/geneediting-revolution-what-crisprcas9.asp#ixzz4Ruzkfihm
http://www.investopedia.com/news/first-human-crispr-geneediting-test-conducted-china-crsp-edit/?partner=YahooSA
A team led by Lu You, an oncologist at Sichuan University in Chengdu, China, has conducted the first human trial of a controversial new gene-editing technology known as CRISPR-Cas9. On October 28, the team injected modified immune cells into a patient with aggressive lung cancer, Nature reported Tuesday afternoon. Carl June, an immunotherapy specialist at the University of Pennsylvania, told the journal he expects the trial "to trigger 'Sputnik 2.0,' a biomedical duel on progress between China and the United States."
Using CRISPR, the team removed the protein PD-1 from immune cells taken from the patient's blood. PD-1 inhibits the immune system's response, allowing tumors to grow. By re-injecting these altered cells, they hope to coax the immune system into attacking the cancer as a disease.
CRISPR's potential applications are already bewildering. It is, in essence, a pair of molecular scissors, which can be used to cut certain strands of DNA out of a sequence and replace them with others. The process often turns out to be imprecise in practice, but at less than five years old, the technology is in its early stages. It is not difficult to envision a future in which scientists can selectively modify any portion of an animal or plant's genome as easily as they might tweak software code. That means increasing crop yields, treating rare genetic diseases for which it's impractical or impossible to develop conventional therapies, rendering disease-carrying pests harmless, and choosing the color of your baby's eyes.
That last example has understandably caused some hang-ups. Many scientists worry about the implications of being able to "design" not just super-productive corn or malaria-free mosquitos, but human beings. The potential pitfalls range from unintended side-effects to a full-fledged eugenics campaign. Poor parents would be unlikely to get to boost their children's height, speed or intelligence, as rich parents may one day be able to do, so economic inequality could take on a genetic element. Most scientists vehemently oppose the use of CRISPR on genes that can be passed on – the "germline" – since, as a number of researchers wrote in a Nature op-ed in March, such modifications "could have unpredictable effects on future generations."
According to Eric Juengst, director of the University of North Carolina Center for Bioethics, the October 28 human trial "does not put the germ-line at risk," so it does not play into the most controversial questions surrounding the technology. "In fact," he told Investopedia via email Tuesday, "similar 'cancer vaccination' protocols have been a common exercise in gene therapy since the 90s." He pointed to a different set of Chinese experiments as a source of controversy, however: in April 2015, it emerged that researchers at Sun Yat-sen University in Guangzhou had modified human germ-line embryo cells. While these were non-viable embryos, many saw the study as crossing a red line.
Besides the ethical questions, there is a question of who owns the intellectual property underpinning a potentially $1.5 billion market (Reportlinker's estimate for 2022). The main contenders are Jennifer Doudna and Emmanuelle Charpantier of Berkeley and Feng Zhang of MIT's Broad Institute. Oral arguments in a dispute between the two sides are set to begin on Thursday. The Berkeley faction is tied to two publicly traded companies, Intellia Therapeutics Inc. (NTLA) and CRISPR Therapeutics Ltd. (CRSP). The Broad Insititute is tied to to Editas Medicine Inc. (EDIT). All three companies went public this year.
Read more: First Human CRISPR Gene-Editing Test Conducted in China (CRSP, EDIT) | Investopedia http://www.investopedia.com/news/first-human-crispr-geneediting-test-conducted-china-crsp-edit/#ixzz4RuwyXIV2
Those interested...the charts below are trying to define themselves "relative" to the 50 day moving average...=BULL above the 50 day...Bear below the 50day...anyone or all of these could become one of those multi-year WOW! stocks...
http://stockcharts.com/c-sc/sc?s=NTLA&p=D&b=5&g=0&i=p18707943583&r=1480898230962
http://stockcharts.com/c-sc/sc?s=CRSP&p=D&b=5&g=0&i=p15600642353&r=1480898336392
http://stockcharts.com/c-sc/sc?s=EDIT&p=D&b=5&g=0&i=p25126586455&r=1480898404309
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
